盐酸坦洛新缓释胶囊治疗良性前列腺增生的药物经济学评价

Pharmacoeconomic Evaluation of Tamsulosin Hydrochloride Sustained-release Capsules in the Treatment of Benign Prostatic Hyperplasia

目的探讨盐酸坦洛新缓释胶囊治疗良性前列腺增生的成本-效果。方法收集2007年9月至2008年10月6所医院的238例良性前列腺增生患者资料,按随机数字表法将患者分为试验组和对照组,各119例,对照组患者服用盐酸坦索罗辛缓释胶囊,试验组患者服用盐酸坦洛新缓释胶囊。比较两组患者药物治疗的成本-效果。结果治疗后,两组患者的IPSS评分均明显低于治疗前、Qmax均明显高于治疗前,差异均有统计学意义(均P<0.05);从增量成本-效果比来看,若多获得一个效果单位,对照组要比试验组多花费98.0元。结论盐酸坦洛新缓释胶囊与盐酸坦索罗辛缓释胶囊在治疗良性前列腺增生方面的综合疗效相同,但前者成本低。

Objective To explore the effect of Tamsulosin Hydrochloride Sustained-release Capsules cost for the treatment of benign prostatic hyperplasia.Methods 6 September 2007 to October 2008 hospital 238 cases of benign prostate hyperplasia patient data collection,the patients were divided into treatment group and control group according to random number table method,119 cases in each,the control group of patients taking tamsulosin hydrochloride sustained-release capsules,treatment group patients taking tamsulosin hydrochloride sustained release capsules.The cost-effectiveness of the two groups of patients was compared.Results After treatment,IPSS score of two groups of patients were significantly lower than the treatment before and Qmax were significantly higher than those before treatment,differences were statistically significant（P〈0.05）;the cost of the treatment group is lower than that of control group,and from the incremental cost-effectiveness ratio,if get an effect unit, the control group than in the treatment group spend more than 98 yuan.Conclusion Integrated efficacy of tamsulosin hydrochloride sustained release capsules and tamsulosin hydrochloride sustained release capsules in the treatment of benign prostatic hyperplasiais the same,but the cost of the former is low.